A Widely Used Drug Shows a New Potential Effect
Semaglutide, the active ingredient in Ozempic and Wegovy, appears to slow the accumulation of DNA markers linked to biological aging in adults with HIV, according to the first randomized, placebo-controlled human clinical trial to examine this question. The study, led by researchers at the University of California San Diego and published in Nature Communications, provides the earliest human clinical evidence that GLP-1 receptor agonist medications may influence aging processes beyond their established effects on weight, blood sugar, and cardiovascular risk.
The finding does not mean semaglutide is an anti-aging drug, and no federal agency has approved it for that purpose. What the research shows is a measurable difference in biological aging rates between adults who received semaglutide injections and those who received a placebo — over 32 weeks of treatment — when aging was measured using multiple validated molecular tools called epigenetic clocks.
Why This Matters
GLP-1 receptor agonist medications have transformed the treatment of obesity and type 2 diabetes in the United States, with millions of prescriptions written annually for semaglutide alone. The question of whether these drugs might also slow aging-related biological processes has become one of the most actively researched areas in longevity science.
This study matters because it moves the question from theoretical to early clinical evidence. Previous research suggesting GLP-1 drugs might influence aging came from laboratory or animal studies or from observational data. A randomized, placebo-controlled trial — even a relatively small and exploratory one — represents a meaningful step up in the quality of evidence.
For the millions of Americans already taking semaglutide for diabetes or obesity management, this study does not change current treatment recommendations. But it adds a new dimension to understanding what these medications may be doing at a cellular level.
What We Know So Far
Researchers at UC San Diego and partner institutions analyzed data from a previously published clinical trial involving 108 adults with HIV-associated lipohypertrophy — a condition in which excess fat accumulates around the abdomen, common in people living with HIV and associated with accelerated aging markers. Approximately half of the participants received weekly injections of semaglutide; the other half received a placebo. The treatment period was 32 weeks.
The research team applied a set of epigenetic clocks — molecular tools that measure biological aging through patterns of chemical modification to DNA called methylation — to assess how each group's cells aged over the trial period. These clocks are validated research instruments used to estimate how fast a person's cells are biologically aging relative to their chronological age.
Across multiple epigenetic clock measures, the semaglutide group showed reduced rates of biological aging compared with the placebo group. The study was published in Nature Communications and was funded in part by the National Institutes of Health.
A related pilot study, published separately in npj Aging, found that semaglutide reduced the pace of biological aging in 42% of participants with HIV and fatty liver disease as measured by the DunedinPACE epigenetic clock. In that study, 34% of participants showed slowed aging associated with all-cause mortality risk, and nearly 49% showed increased telomere length — the protective caps on chromosomes associated with cellular longevity.
Local and Population Context
HIV is one of several conditions associated with accelerated biological aging. People living with HIV often show epigenetic aging patterns years ahead of their chronological age — a phenomenon researchers believe is driven by persistent immune activation and chronic inflammation, even when viral loads are well-controlled by antiretroviral therapy.
The UC San Diego research group chose to study semaglutide in this population specifically because the biological aging processes most relevant to GLP-1 drugs appear earlier and more prominently in people with HIV, making them a useful population for detecting effects that might also apply more broadly.
Michael Corley, PhD, associate professor of medicine in the Division of Geriatrics, Gerontology and Palliative Care at UC San Diego School of Medicine and the Stein Institute for Research on Aging, explained the research rationale: "Many of the biological processes we study in HIV are also central to aging in the general population. Because these processes can emerge earlier or be more pronounced in people with HIV, this community can help us identify interventions that may improve healthspan more broadly."
What Doctors and Experts Say
Dr. Corley described the proposed mechanism through which semaglutide may influence aging: the drug reduces visceral fat — the metabolically active fat stored deep in the abdomen — and lowers markers of chronic inflammation. Both visceral fat accumulation and chronic inflammation are independently linked to accelerated biological aging across multiple organ systems.
By addressing these two upstream drivers, researchers believe semaglutide may be influencing molecular aging pathways in ways that extend beyond its primary mechanisms of action on blood sugar and appetite.
Independent researchers in the aging science community have noted that the study's use of multiple validated epigenetic clocks — rather than a single measure — adds credibility to the findings, because consistent results across several different molecular aging tools are less likely to reflect measurement artifact.
The funding for the study came from the National Institutes of Health and the James B. Pendleton Charitable Trust, with no pharmaceutical industry funding disclosed.
What the Evidence Shows and What It Does Not
This is an important finding — and it comes with important limitations that MedicalDaily considers essential to report accurately.
First, the epigenetic aging analysis was a post hoc, exploratory analysis. This means it was not pre-specified as the primary endpoint of the original clinical trial, which was designed to measure changes in visceral fat. Exploratory post hoc analyses can generate useful hypotheses and early signals, but they carry a higher risk of false-positive findings than pre-specified primary outcomes.
Second, the study population was specific: adults with HIV and lipohypertrophy. Whether semaglutide would show the same anti-aging effects in people without HIV, in older adults without metabolic dysfunction, or in populations with different body compositions and health backgrounds remains unknown.
Third, 84 participants completed the full 32-week protocol (45 semaglutide, 39 placebo) — a sample size that is appropriate for early-phase research but is not large enough to draw definitive conclusions about the drug's effects on aging across diverse populations.
Fourth, epigenetic clock measurements reflect biological aging at a molecular level, but they are not the same as clinical outcomes. Slowing an epigenetic clock does not guarantee a reduction in dementia, cardiovascular disease, or other age-related conditions. Long-term outcome data would be needed to confirm those connections.
MedicalDaily Evidence Check
- Study type: Post hoc exploratory epigenetic analysis of a Phase 2b, randomized, double-blind, placebo-controlled clinical trial
- Published in: Nature Communications (June 2026)
- Participants: 84 adults with HIV-associated lipohypertrophy (45 semaglutide, 39 placebo)
- What it found: Semaglutide reduced biological aging rates across multiple epigenetic clocks compared with placebo over 32 weeks
- Key limitation: Post hoc, exploratory analysis; study population limited to adults with HIV; does not prove clinical anti-aging outcomes
- What it does not prove: That semaglutide extends lifespan, prevents age-related disease, or produces the same effects in people without HIV
- Funding: National Institutes of Health and James B. Pendleton Charitable Trust; no pharmaceutical industry funding disclosed
- Current medical guidance: Semaglutide is approved by the FDA for type 2 diabetes management (Ozempic) and chronic weight management (Wegovy); it is not approved for anti-aging indications
Who Faces the Greatest Interest in This Research
The clinical trial focused on adults living with HIV, particularly those experiencing lipohypertrophy. However, the broader research question — whether GLP-1 drugs slow biological aging — is relevant to:
- People already prescribed semaglutide for diabetes or obesity management who want to understand whether additional biological effects are possible
- Older adults and their clinicians exploring whether GLP-1 medications might serve additional preventive functions in aging
- People living with HIV , for whom accelerated biological aging is a documented clinical challenge
- Researchers in aging science , who are now actively pursuing follow-up trials in broader populations
- Adults with visceral obesity or metabolic syndrome , which share key biological pathways with the conditions studied in this trial
It is important to note that semaglutide carries significant side effects for many people, including nausea, vomiting, and gastrointestinal discomfort. It is a prescription medication requiring clinical supervision and is not appropriate for everyone. The findings from this study should not be used as justification to seek semaglutide for anti-aging purposes outside of an approved indication and physician guidance.
Symptoms, Side Effects, and What to Watch For
For people currently taking semaglutide or considering it for an approved indication, the most common side effects reported in clinical trials include:
- Nausea (most common, particularly when starting or increasing the dose)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Decreased appetite
More serious but less common risks include pancreatitis, gallbladder disease, increased heart rate, kidney problems related to dehydration, and — in rare cases — thyroid tumors (seen in animal studies; human risk uncertain). People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are advised not to take semaglutide, according to FDA prescribing guidance.
Any new or worsening symptoms while taking semaglutide should be reported to a clinician promptly.
What You Can Do Now
- If you are currently taking semaglutide for an approved purpose , this research is interesting context but does not require you to change anything. Discuss the findings with your prescribing clinician if you have questions.
- Do not seek semaglutide specifically for anti-aging purposes based on this early evidence. It is a prescription medication with side effects and is not FDA-approved for longevity or aging indications.
- Talk with your doctor about whether GLP-1 medications are appropriate for you if you have type 2 diabetes or obesity — those remain the established, evidence-based indications.
- Monitor this research area. Several larger clinical trials examining GLP-1 drugs and aging in broader populations are underway. Results from those studies will provide much clearer guidance than this early exploratory trial.
- Maintain evidence-based healthy aging practices in the meantime: regular physical activity, a diet rich in vegetables and whole foods, adequate sleep, and management of chronic conditions including high blood pressure and diabetes — all of which independently reduce biological aging markers.
Cost and Access: What Patients Should Know
Semaglutide remains expensive without insurance coverage. The retail list price for Wegovy (the obesity formulation) runs over $1,300 per month, though Novo Nordisk's patient assistance programs may reduce or eliminate out-of-pocket costs for eligible patients.
For patients with type 2 diabetes, Ozempic is more likely to be covered by commercial insurance and Medicare Part D, though prior authorization requirements vary by plan. Generic semaglutide formulations are not yet available in the United States. Compounded versions have been available during shortage periods but are not equivalent to FDA-approved formulations.
Patients seeking GLP-1 medications should work with a licensed prescriber rather than online vendors offering prescriptions without proper clinical evaluation.
What Happens Next
The UC San Diego research team and collaborators at Harvard, Johns Hopkins, the University of Southern California, and the University of Texas are continuing to study semaglutide's effects on biological aging in broader populations. The findings from the current trial are expected to inform the design of larger, prospective clinical studies with pre-specified aging endpoints that would generate more definitive evidence.
The npj Aging pilot study and the Nature Communications trial together represent the foundation of a growing research program. Peer review of the findings will continue, and independent research groups are expected to pursue replication studies.
MedicalDaily will report on follow-up trials, peer commentary, and FDA developments in this area as they emerge.
The Bottom Line
The first human clinical trial evidence that semaglutide may slow biological aging is genuinely interesting science from a credible institution, published in a peer-reviewed journal with NIH funding. But it is early, exploratory, and limited to a specific population. It does not change current prescribing guidelines, it does not make semaglutide an anti-aging drug, and it does not mean people should seek the medication outside of its established indications. What it does is open a scientifically serious door to investigating whether a widely used medication class might have benefits that extend meaningfully into healthy aging — a question that larger, prospective trials are now in a position to answer.
